12.05.16

BMH BRÄUTIGAM ADVISES PRIMA BIOMED IN A$400 MILLION CROSS-BORDER SPIN OUT

BMH BRÄUTIGAM led a team comprising German, Australian and U.S.-American lawyers for out-licensing Prima BioMed’s CVac immuno-oncology through a cross-border spin out.

Prima BioMed is a globally active Sydney-based biotechnology company with branches in Germany and France. It is listed in Australia (ASX) and the United States (NASDAQ). Licensee is U.S.-based and U.S.-listed Sydys Corporation. Along with the license for CVac, it acquired various CVac-related assets. Prima BioMed receives performance-based payments up to A$400 million (US$ 293 million) as well as 9.9% equity stake in Sydys. As background: Prima Biomed is a loyal client of BMH BRÄUTIGAM. The contact was made by CEO Marc Voigt, who formerly served as board-member for Medical Enzymes AG. Dr. Patrick Hohl has advised Medical Enzymes AG in various transactions. BMH BRÄUTIGAM Team: Dr. Patrick Hohl, Dr. Alexander Wulff, Katharina Erbe (M&A | Venture Capital)